Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01444209 |
Recruitment Status :
Terminated
(Failure to accrue)
First Posted : September 30, 2011
Results First Posted : November 30, 2021
Last Update Posted : November 30, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pituitary Macroadenoma | Radiation: Iodine Implants | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Interstitial Radioactive Iodine Implants for the Treatment of Pan-invasive Pituitary Macroadenomas |
Actual Study Start Date : | September 30, 2011 |
Actual Primary Completion Date : | October 20, 2020 |
Actual Study Completion Date : | January 20, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Radiation Therapy
Interstitial Radioactive Iodine Implants
|
Radiation: Iodine Implants
Interstitial Radioactive Iodine Implants |
- Partial Response (Reduction in 30% of Tumor Volume) or Greater Response Within 12 Months From the Implant Procedure. [ Time Frame: 12 months ]
- Change of the Patient's Humphrey Visual Field Testing [ Time Frame: 5 years ]
- Potential Toxicities Associated With Interstitial Seed Placement [ Time Frame: 5 years ]
- Progression Free Survival [ Time Frame: 5 years ]
- The Effect of the Treatment on Quality of Life Evaluations (Patient Reported Outcomes) [ Time Frame: 5 years ]
- The Cost-utility of the Treatment Arm (in Terms of the Primary Outcome) in Comparison With Other Widely Accepted Cancer and Non-cancer Therapies [ Time Frame: 5 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pathological or radiographic diagnosis of a pan-invasive pituitary macroadenoma
- Pan-invasive for the purposes of the protocol will be defined as meeting each of the following 2 major criteria: (1). tumor volume greater than 20 cc at enrollment, and (2). suprasellar extension. In addition, a pan-invasive tumor must meet any one of the following 3 minor criteria, a) unresectable tumor invasion into a cavernous sinus, b) bone or bone marrow invasion into the clivus or temporal bones, or c) tumor extension in any direction unlikely to be completely removed by specifically a transphenoidal surgical approach.
- Patients who meet the two major criteria above (1 and 2) and are medically inoperable for tumor resection (due to confounding co-existing medical problems) are eligible without meeting any of the three minor criteria (a, b, or c).
- Patients should be immediately threatened for vision loss or other significant neurological impairment directly related to tumor mass effect. As such, all patients enrolled would likely benefit from tumor response (shrinkage).
- Patients must have visible tumor on imaging studies (MRI or CT)
- The patient's Zubrod performance status must be 0-3.
- Patients must be at least 18 years of age.
- Mandatory Imaging Studies: Must be done 45 or fewer days prior to :
MRI or CT scan of the brain including the entire skull base and all areas of tumor extension
Exclusion Criteria:
- Patients who are unable to undergo general anesthesia
- Patients who are unable to undergo placement of a stereotactic head frame
- Patients who are unable to provide informed consent
- Patients who are pregnant or nursing
- Patients with severe kidney dysfunction
- Patients who have contraindications to MRI, such as implanted pacemaker device
- Patients with diagnosis of pituitary carcinoma

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01444209
United States, Texas | |
University of Texas Southwestern Medical Center | |
Dallas, Texas, United States, 75390 |
Principal Investigator: | Robert Timmerman, MD | University of Texas Southwestern Medical Center |
Documents provided by Robert Timmerman, University of Texas Southwestern Medical Center:
Responsible Party: | Robert Timmerman, Professor, University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT01444209 |
Other Study ID Numbers: |
STU 042011-075 |
First Posted: | September 30, 2011 Key Record Dates |
Results First Posted: | November 30, 2021 |
Last Update Posted: | November 30, 2021 |
Last Verified: | November 2021 |
pituitary gland |
Pituitary Diseases Hypothalamic Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Endocrine System Diseases |